60 Day FRN

80105

Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of respondents

Agency Stakeholders ......................................

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–27322 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-21–21BL; Docket No. CDC–2020–
0120]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled, ‘‘Evaluation of the Overdose Data
to Action Technical Assistance Hub’’.
This proposed collection will be used to
monitor and evaluate the effectiveness
and impact of technical assistance (TA)
provided to Overdose Data to Action
(OD2A) program recipients funded to
implement opioid surveillance and
prevention efforts in their jurisdictions.
DATES: CDC must receive written
comments on or before February 9,
2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0120 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for

jbell on DSKJLSW7X2PROD with NOTICES

SUMMARY:

VerDate Sep<11>2014

23:25 Dec 10, 2020

Jkt 253001

Number of
respondents

Form name
SMS Text Survey ...........................................
ACAS Sign In Sheet ......................................
Hardcopy ACAS .............................................
Online ACAS ..................................................
SMS Text Survey ...........................................

Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;

PO 00000

Frm 00116

Fmt 4703

Sfmt 4703

150
42
26
16
50

Number of responses per
respondent
1
1
1
1
1

Avg. burden
per response
(in hrs.)
3/60
2/60
15/60
15/60
3/60

3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Evaluation of the Overdose Data to
Action Technical Assistance Hub—
New—National Center for Injury
Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Division of Overdose Prevention
(DOP), at Centers for Disease Control
and Prevention (CDC) requests a threeyear OMB approval to support the
evaluation of technical assistance (TA)
provided for the Overdose Data to
Action (OD2A) program. OD2A is a
cooperative agreement (CDC–RFA–
CE19–1904) funded in 2019 to focus on
comprehensive and interdisciplinary
opioid overdose prevention efforts in 47
state health departments, 16 localities,
Puerto Rico, Washington DC, and the
North Mariana Islands. This program
consists of two required components– a
surveillance component and a
prevention component. OD2A recipients
implement a combination of activities
across ten strategies within these
components in order to gain access to
high quality, complete, and timelier
data on opioid prescribing and
overdoses and to use those data to
inform prevention and response efforts
in their jurisdictions.
Training and technical assistance
(TA) is essential to building knowledge
and strengthening the capacity of
recipients to implement and evaluate
OD2A program strategies. CDC will
develop and deploy a TA hub (hereafter
referred to as the OD2A TA Center) to
deliver comprehensive technical
assistance and training to support the

E:\FR\FM\11DEN1.SGM

11DEN1

80106

Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices

successful implementation and
evaluation of surveillance and
prevention activities. The OD2A TA
Center is designed to enhance the
efficiency, coordination, and
effectiveness of TA efforts by
streamlining and centralizing the
provision of overdose surveillance and
prevention TA. TA to OD2A recipients
is divided into four different levels with
multiple modes of TA delivery and
involves a wide range of TA providers
including CDC staff, internal and
external subject matter experts (SMEs)
and program partners as well as ICF
staff.

obtained through this evaluation will
allow TA providers to assess OD2A
recipients’ experience and utility of
knowledge and resources gained
through individual TA support, peer-topeer sessions, and other group trainings.
Ultimately, the evaluation data will
inform subsequent rounds of TA and
allow TA providers to make necessary
adjustments to the overall TA strategy
for continuous quality improvement.
This will ensure recipients have the
support necessary to implement
strategies that will improve opioid
surveillance and prevention policies
and practices within their communities.

The evaluation consists of two webbased surveys designed to collect
process and outcome measures about
TA access, utilization, and outcomes
across all 66 OD2A recipient programs.
The Technical Assistance Feedback
Form will be administered to collect
immediate feedback following
individual TA encounters and group
events such as webinars and in-person
trainings. The Annual OD2A TA Survey
will be distributed twice (mid-point and
final) to assess satisfaction with overall
TA provided and the extent to which
TA supports informed implementation
of OD2A strategies. The information

ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)

Total burden
(in hours)

Form name

OD2A Recipients ..............................
Annual OD2A TA Survey ..................

TA Feedback Form ..........................
...........................................................

671
440

2
1

5/60
15/60

112
110

Total ...........................................

...........................................................

........................

........................

........................

222

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–27325 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–20OT]

Agency Forms Undergoing Paperwork
Reduction Act Review

jbell on DSKJLSW7X2PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Type of respondents

In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Mycoplasma
genitalium Treatment Failure Registry’’
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on June 5, 2020 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget

VerDate Sep<11>2014

00:32 Dec 11, 2020

Jkt 253001

is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written

PO 00000

Frm 00117

Fmt 4703

Sfmt 4703

comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Mycoplasma genitalium Treatment
Failure Registry—New—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC), Division of STD
Prevention requests a three-year
approval of an information collection
request for the Mycoplasma genitalium
Treatment Failure Registry, which will
entail use of a standardized Case Report
Form.
The primary goal of this activity is to
establish a registry to monitor cases of
Mycoplasma genitalium (M. genitalium)
treatment failure in the United States.
The project objectives are as follows: (1)
Using existing clinical data, describe
demographic and behavioral factors
among patients with documented
Mycoplasma genitalium who fail
current CDC-recommended treatment,
(2) Using existing clinical data, describe
antibiotic regimens utilized among
patients with Mycoplasma genitalium
treatment failure, including
documentation of clinical and

E:\FR\FM\11DEN1.SGM

11DEN1